Jeffrey Cleland, Ph.D., chairman, chief executive officer and president of Ashvattha Therapeutics, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020.
Ashvattha Therapeutics Subsidiary Orpheris Enrolls First Patients in Phase 2 PRANA Clinical Study Evaluating OP-101 for Severe COVID-19
Orpheris, a subsidiary of Ashvattha, announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe COVID-19.
Ashvattha Therapeutics Subsidiary Orpheris Announces Completion of Phase 1 Study of OP-101 Subcutaneous Formulation
Orpheris, a subsidiary of Ashvattha, announced results from a Phase 1 single administration study evaluating the subcutaneous (SC) formulation of OP-101 (4 or 8 mg/kg) in healthy volunteers.
Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients
Orpheris, a subsidiary of Ashvattha, announced the FDA has agreed to a Phase 2 clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of OP-101 in patients with severe COVID-19
Ashvattha Therapeutic has been selected to present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in June, 2020.
Ashvattha Therapeutics Unveils Transformative Dendrimer-based anti-VEGF Treatment for Retinal Diseases at ARVO 2020
Company to develop subcutaneously administered dendrimer-based anti-VEGF therapy with selective targeting in wet AMD. Potential therapeutic may offer significant opportunities for degenerative retinal diseases such as wet AMD and diabetic retinopathy, and may reduce significant side effects associated with systemic treatment of ocular disease.